Sirolimus Based Nano Carrier Eluting Stent System
- UID
- G/28/1396_95b8dfa03b2965ebe49535e998d84f7b_6944669de5c8a4a4a7107b15f5836f04
- Device class
- Class D
- Brand name
- Devoir, Vanquisher
- License holder
- Envision Scientific Pvt. Ltd.
- Approving authority
- Central Drug Standards Control Organization, Ahmedabad
- Product information
- The Sirolimus Based Nano Carrier Eluting Stent System is intended for use in the treatment of patients with clinical symptoms of myocardial ischemia related to the pathological condition of one or more coronary arteries. Recognized use of intracoronary stents currently includes but is not limited to the treatment of de novo or restenotic lesions in native coronary arteries and in de novo lesions of saphenous vein grafts. The Sirolimus Based Nano Carrier Eluting Stent System is available for intracoronary implantation for inner vessel diameters of 2.25 to 4.00 mm
Sirolimus Based Nano Carrier Eluting Stent System is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID G/28/1396_95b8dfa03b2965ebe49535e998d84f7b_6944669de5c8a4a4a7107b15f5836f04. This device is marketed under the brand name Devoir, Vanquisher. The license holder is Envision Scientific Pvt. Ltd., and it is classified as Device Class Class D. The approving authority is Central Drug Standards Control Organization, Ahmedabad.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.